NICE approval for arthritis antibody

Patients with rheumatoid arthritis can now be treated with tocilizumab (RoActemra) on the NHS.

Tocilizumab is a humanized monoclonal antibody that prevents interleukin-6 binding to its receptor.
Tocilizumab is a humanized monoclonal antibody that prevents interleukin-6 binding to its receptor.

NICE has recommended tocilizumab, in combination with methotrexate, for the treatment of moderate to severe rheumatoid arthritis that has not responded to other TNF inhibitors. Patients must have also either failed to respond to, or be unsuitable, for treatment with rituximab.

Patients already receiving tocilizumab who do not meet the above criteria should be able to continue treatment until they and their doctor decide it is appropriate to stop, says NICE.

NICE has previously approved the TNF inhibitors adalimumab, etanercept, infliximab and certolizumab pegol for the treatment of rheumatoid arthritis.

NICE guidance on tocilizumab

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more